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Abstract A multicenter, double-blind, randomized study
was conducted to assess the effect of caffeine on regade-
noson stress myocardial perfusion imaging (MPI). Subjects
with a high likelihood of coronary artery disease underwent
a rest single-photon emission computed tomography MPI
on day 1 (MPI-1) and a stress MPI with regadenoson on day
3 (MPI-2). Individuals with C1 segment with a reversible
defect received double-blind caffeine tablets (200 or
400 mg) or placebo 90 min before a repeat regadenoson
stress MPI (MPI-3) on day 5. Overall, 207 subjects com-
pleted the study (caffeine 200 mg, n = 70; caffeine
400 mg, n = 71; placebo, n = 66). The mean number of
segments with reversible defects decreased from MPI-2 to
MPI-3 in the caffeine 200 and 400 mg groups versus no
significant change in the placebo group [mean ± standard
deviation: -0.61 ± 1.097, -0.62 ± 1.367, and 0.12 ±
0.981, respectively (overall treatment effect, P \ 0.001)].
The majority of subjects who received caffeine shifted to a
lower ischemia size category from MPI-2 to MPI-3, with no
clear pattern observed in subjects who received placebo.
For caffeine exposed patients with C3 segments with
reversible defects at MPI-2, 21/23 had fewer detected at
MPI-3. Both the 200 and 400 mg doses of caffeine signif-
icantly reduced the number of segments with reversible
defects detected by regadenoson stress MPI.
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Introduction
Regadenoson was approved by the United States Food and
Drug Administration in 2008 as a pharmacologic stress
agent for myocardial perfusion imaging (MPI) in subjects
unable to undergo adequate exercise stress [1]. The special
features of this adenosine A2A receptor agonist have been
reviewed previously [2]. Additionally, Phase 4 trials have
assessed the safety and tolerability of regadenoson in
patients with chronic kidney disease and in those with
asthma or chronic obstructive pulmonary disease [3, 4].
Caffeine is a nonspecific competitive antagonist of all
adenosine receptor subtypes [5, 6]. Therefore, caffeine may
interfere with the coronary vasodilatory effects of adeno-
sine agonists through its effects on A2A receptors, which
mediate coronary vasodilation [7]. A large majority of the
adult population consumes caffeine daily, and the possible
interaction of caffeine on the accuracy of stress testing with
agents such as regadenoson is an important clinical issue.
Regadenoson prescribing information [1] and current
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American Society of Nuclear Cardiology (ASNC) imaging
guidelines [8] both recommend that caffeine and other
methylxanthine-containing compounds be withheld for
12 h before vasodilator stress MPI. A previous study
showed that moderate oral caffeine intake (200 mg) did not
significantly affect regadenoson-induced myocardial blood
flow as assessed by positron emission tomography (PET) in
41 healthy individuals [9]. However, that study did not
evaluate the effect on the detection of reversible perfusion
defects by single-photon emission computed tomography
(SPECT).
The objective of the current study was to determine
whether the prior administration of caffeine affects the
diagnostic accuracy of regadenoson-stress SPECT MPI for
detecting reversible defects in subjects with a high likeli-
hood of coronary artery disease (CAD). The safety and
tolerability of concomitant caffeine and regadenoson
administration were also assessed. A detailed discussion of
the rationale and description of the study design has been
published previously [10].
Methods
This Phase 3b, double-blind, randomized, placebo-con-
trolled, parallel-group study (NCT00826280) was con-
ducted at 24 sites in the United States from 24 March 2009
(first subject enrolled) to 15 July 2010 (last evaluation).
Participant selection
The study involved clinically stable male and female out-
patients C18 years of age, with a high likelihood of having
ischemia on testing, but with an intermediate or low risk of
needing immediate coronary intervention. The subjects
were also regular caffeine consumers (C1 cup of caffei-
nated coffee per day or equivalent). Key inclusion and
exclusion criteria have been detailed previously [10].
Study design
Subjects were screened during a first clinic visit. MPI was
conducted on days 1, 3, and 5 as follows: (1) day 1
(baseline): rest MPI (MPI-1); (2) day 3: stress MPI with
open-label regadenoson 400 lg (MPI-2). Subjects with C1
segment with a reversible defect, as read by the site, (if the
apex was involved, then an additional reversible segment
had to be present) continued to MPI-3; (3) day 5: stress
MPI (MPI-3) in a double-blind, randomized sequence
(1:1:1) with regadenoson ? placebo, regadenoson ? caf-
feine 200 mg, or regadenoson ? caffeine 400 mg. The
caffeine intake was approximately equivalent to 2–4 cups
of coffee (moderately high). If a subject was subsequently
determined not to have C1 segment with a reversible defect
according to the core imaging laboratory reading, the
subject was discontinued. Regadenoson was administered
90 min after placebo or caffeine intake. A follow-up safety
visit was scheduled for 24 h after study drug administration
at MPI-3 to identify any unforeseen side-effects. Sub-
sequent clinical management was at the discretion of the
investigator and based only on the results of the MPI-1
(rest) and MPI-2 (stress) scans.
Imaging protocol
Regadenoson 400 lg was administered as a 10-s intrave-
nous 5 mL injection followed by a 5 mL saline flush. The
radiotracer (10–15 mCi of technetium-99 m sestamibi or
tetrofosmin) was administered 10–20 s after regadenoson.
SPECT MPI acquisition was started 60–90 min later using
standard protocols as described in the ASNC guidelines
[8]. The same radiotracer was used across all three MPI
procedures for each subject.
Theophylline or theophylline-containing medications
were withheld for 7 days before randomization and for the
study duration. Caffeinated foods and beverages, dipyrid-
amole, and calcium channel blockers were prohibited for
24 h and nitrates for 12 h before any visit.
The study was conducted in compliance with the prin-
ciples of the International Conference on Harmonization of
Technical Requirements for Registration of Pharmaceuti-
cals for Human Use and Good Clinical Practice. The pro-
tocol was approved by the Institutional Review Board/
Independent Ethics Committee of each study site. Each
subject provided written informed consent prior to any
study-related procedures.
Imaging analysis
All MPI images for subjects completing the study were
interpreted by three independent, blinded readers at a central
core imaging laboratory. In addition to visual interpretation
by the readers, the images were assessed by computerized
quantitation using the Emory Cardiac ToolboxTM (Synter-
med, Inc., Atlanta, GA, USA). The number of reversible
ischemic defects was assessed using a 17-segment model
[11]. Segments were considered to have a reversible defect if
the stress perfusion score exceeded the rest score and the
stress score was C2. Scores were based on tracer activity in
each segment on a 5-point scale for radiotracer uptake:
0 = normal uptake; 1 = slightly reduced uptake;
2 = moderately reduced uptake; 3 = severely reduced
uptake; and 4 = absent uptake. Total scores across all 17
segments were generated as follows: the summed stress
score (SSS); the summed rest score (SRS); and the summed
difference score (SDS), calculated as the difference between
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the SSS and SRS. Independent review of SPECT MPI data
was facilitated by a configuration of two compliant com-
puterized systems working in tandem: (1) the image review
software (Emory Cardiac ToolboxTM; Syntermed, Atlanta,
GA, USA) and (2) the data capture system incorporating the
electronic case report form.
The primary efficacy variable was the change in number
of segments with reversible defects between MPI-2 (reg-
adenoson alone) and MPI-3 (regadenoson ? placebo or
caffeine). Secondary efficacy variables included the change
in SDS between MPI-2 and MPI-3, and agreement rates
between MPI-2 and MPI-3 according to ischemia size
category (0 to \2, 2 to \5, and C5 segments with revers-
ible defects, consistent with the categorization applied in
the Phase 3 regadenoson trials) [12, 13].
Safety assessments
Safety was assessed throughout the trial, based on vital
signs, adverse events, laboratory assessments, blood car-
diac markers (CPK-MB, CPK-MB fraction, and troponin
T), and 12-lead electrocardiographs.
Statistical analyses and sample size calculation
An analysis of variance (ANOVA) and Fisher’s least sig-
nificant difference with a type 1 error rate of 5 % was used
to test for significantly different mean changes in the
number of segments with reversible defects among the
treatment arms. This approach was able to detect a change
of ±1 reversible defect relative to placebo with 95 %
power for 200 subjects randomized 1:1:1 with a standard
deviation (SD) similar to that observed in the Phase 3 trials
(SD = 1.59), and with placebo having a mean effect of 0
on the change in number of segments with reversible
defects.
The full analysis set comprised all randomized subjects
with 3 interpretable MPI scans, the per-protocol set com-
prised a subset of full analysis subjects with no major pro-
tocol deviations, and the safety analysis set comprised all
subjects who received C1 dose of regadenoson. Subsets of
patients with C3 segments with reversible defects at MPI-2
and with SDS scores C2 were also examined, to quantify
results in patients with a greater disease burden. The two
caffeine dose groups were combined for subset analyses.
For the primary efficacy variable, an analysis of
covariance (ANCOVA) was used with treatment arm as a
factor and the number of segments with reversible defects
at MPI-2 as a covariate. Fisher’s least significant difference
was used to test for an overall treatment arm effect using a
5 % type 1 error rate.
Additional analyses were conducted on the full analysis
set to determine agreement between MPI-2 and MPI-3 with
respect to ischemia size category using the median count
across the three independent readers. The agreement rate
and a 95 % Clopper–Pearson confidence interval (CI) was
calculated for each ischemia size category within each
treatment arm. The difference in agreement rate between
the treatment arms and associated 95 % CI was also cal-
culated for each ischemia size category. A test of marginal
homogeneity was performed for each treatment arm.
A Cochran–Mantel–Haenszel test of equality of mean
scores between MPI-2 and MPI-3 was performed using the
following scoring system: 0 to \2 = 0; 2 to \5 = 1; and
C5 = 2.
The variability of the change in number of segments
with reversible defects for the caffeine 200 and 400 mg
arms was compared with the placebo arm. Levene’s test
was performed with a 5 % type 1 error rate to test for an
increase in the variance of each caffeine arm versus pla-
cebo if the variance of a caffeine group was greater than
the placebo group.
The overall change in SDS was analyzed using the same
methods as the primary analysis, with the corresponding
variable at the initial stress scan used as a covariate.
To examine if caffeine consumption lowered the rate of
headaches, a generalized estimating equation was used due
to the correlation between repeated measurements on the
same subject. A logistic model was fitted with the dichot-
omized values of Headache or No headache and to assess
the significance of treatment effect.
Results
Study population
Of the 347 subjects randomized, 345 received at least one
dose of study drug (safety analysis set) (Fig. 1). The full
analysis set included 207 subjects. The absence of a
reversible ischemic defect at MPI-2 was the major reason
for study discontinuation. A total of 29 patients had C3
segments with reversible defects at MPI-2.
Baseline demographic and clinical characteristics were
generally consistent between the regadenoson ? placebo
and regadenoson ? caffeine groups (Table 1). The major-
ity of the study population was comprised of white males.
Efficacy analyses
Example images are shown in Fig. 2. The mean (±SD)
number of segments with reversible defects based on
blinded reader assessment did not change significantly
from MPI-2 to MPI-3 in the placebo group (0.12 ± 0.981;
P = 0.3192), but decreased in the caffeine 200 mg
(-0.61 ± 1.097; P \ 0.001 vs. placebo) and 400 mg
Int J Cardiovasc Imaging (2014) 30:979–989 981
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Fig. 1 Patient disposition. *Data was not collected on the number of subjects screened, only those randomized. Received randomized treatment
at MPI-3 (regadenoson plus placebo or caffeine). All subjects with interpretable MPI-1, MPI-2, and MPI-3 scans
Table 1 Baseline demographics and clinical characteristics (full analysis set)
Regadenoson ? placebo
(n = 66)
Regadenoson ? caffeine 200 mg
(n = 70)a
Regadenoson ? caffeine 400 mg
(n = 71)
P value
Sex, n (%) 0.1842
Male 55 (83.3) 58 (82.9) 51 (71.8)
Female 11 (16.7) 12 (17.1) 20 (28.2)
Ethnicity, n (%) 0.8753
Non- Hispanic or Latino 60 (90.9) 64 (91.4) 63 (88.7)
Hispanic or Latino 6 (9.1) 6 (8.6) 8 (11.3)
Race, n (%) 0.7030
White 61 (92.4) 63 (90.0) 68 (95.8)
Black/African American 5 (7.6) 5 (7.1) 3 (4.2)
Other 0 2 (2.9) 0
Age (years) 0.0858
Mean ± SD 68.0 ± 10.0 65.7 ± 11.1 69.4 ± 8.2
Range 43–91 32–86 46–86




Beta-blocking agents 52 (78.8) 59 (84.3) 58 (81.7)
SD standard deviation
 To compare for differences across treatment groups, a 1-way analysis of variance was used for continuous variables and Fisher’s exact test
(2-tailed) was used for the discrete variables
a Unless otherwise stated
b n = 69
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(-0.62 ± 1.367; P \ 0.001 vs. placebo) groups
(P \ 0.001 for the overall treatment effect; Table 2). The
mean change using automated quantitation was consistent
with the results from the blinded reader analysis (Table 2).
There was no significant difference between the two caf-
feine dose groups (P = 0.9328; Table 2).
The total number of segments with reversible defects
detected (the sum of the median response for the three
blinded readers) was 2.6-fold lower from MPI-2 to MPI-3
in the combined 200 and 400 mg caffeine groups, whereas
there was little difference from MPI-2 to MPI-3 in the
placebo group (Fig. 3). In the subset of patients with C3
segments with reversible defects at MPI-2, the median
number of segments with reversible defects at MPI-2 and
MPI-3 indicated that fewer reversible defects were detected
following caffeine (200 and 400 mg groups combined),
whereas there was no such pattern in the placebo group
(Fig. 4). Of these caffeine exposed patients, 21/23 with C3
segments with reversible defects at MPI-2 had fewer
defects detected at MPI-3. Of the subjects who received
caffeine, 26/36 (72 %) of subjects with 2 to \5 segments
with reversible defects and 1/5 (20 %) of subjects with C5
Fig. 2 Example images.
Patient 1 images show a
predominantly reversible
inferior left ventricular defect
(yellow arrows), and a
predominantly reversible defect
at the left ventricular apex
(white arrows). Both defects are
more intense after regadenoson
stress (b) than after regadenoson
plus caffeine 200 mg (c). There
is also a nonreversible defect
infero-laterally. Patient 2
images show a partially
reversible inferior left
ventricular defect (white
arrows). The defect is larger and
more intense after regadenoson
stress (b) than after regadenoson
plus caffeine 200 mg (c)
Int J Cardiovasc Imaging (2014) 30:979–989 983
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segments with reversible defects at MPI-2 shifted to the
non-ischemic category (0–1 defects) at MPI-3. Therefore, a
total of 27/41 (66 %) shifted from ischemic to non-ische-
mic and 3/100 (3 %) subjects shifted from non-ischemic to
ischemic. In the placebo group, 4/14 (29 %) subjects
shifted from ischemic to non-ischemic, and 5/52 (10 %)
shifted from non-ischemic to ischemic.
The mean (±SD) change in SDS from MPI-2 to MPI-3,
as assessed by the blinded readers, increased slightly in the
placebo group (0.11 ± 2.871), but decreased in the caf-
feine 200 mg (-1.03 ± 2.071; P = 0.0034 vs. placebo)
and 400 mg (-1.25 ± 2.664; P \ 0.001 vs. placebo)
groups (P = 0.0011 for the overall treatment effect;
P = 0.5902 for comparison of the two caffeine doses). In
the subset of patients with an SDS response C2 (n = 100),
a general trend towards a lower score following caffeine
(200 and 400 mg groups combined) was observed, whereas
there was no such pattern in the placebo group (Fig. 5). Of
these caffeine-exposed patients, 31/68 had a lower SDS at
MPI-3 compared with MPI-2, whereas 37/68 had an
increase or no change in SDS.
Reader agreement rates by the extent of ischemia
(0 to \2, 2 to \5, and C5 reversible segments) were sig-
nificantly different between MPI-2 and MPI-3 for both
caffeine groups, whereas there was no significant differ-
ence in the placebo group (Table 3). For both caffeine
groups combined, 26/36 (72 %) of subjects with 2 to \5
reversible segments and 5/5 (100 %) with C5 reversible
segments at MPI-2 shifted to a lower category at MPI-3
(i.e., less ischemia was detected). There was no clear pat-
tern in the placebo group (Table 3). Overall, agreement
rates in the caffeine groups tended to decrease as the
ischemia extent increased, being highest for the 0 to \2
category and poorest for the C5 category (although sample
sizes were small in the latter category).
Transient ischemic dilatation (TID) was not coded
prospectively by the core lab readers. The extent of
ischemia was quite modest in most patients and based on
Table 2 Mean number and mean change in number of segments with reversible defects between MPI-2 and MPI-3, as assessed by blinded




200 mg (n = 70)
Regadenoson ? caffeine




Number of segments with reversible
defects, mean ± SD
MPI-2 (regadenoson alone) 0.67 ± 1.377 1.01 ± 1.452 1.00 ± 1.595
MPI-3 (regadenoson ? placebo or
caffeine)
0.80 ± 1.511 0.40 ± 0.907 0.38 ± 0.962
Change in number of segments with
reversible defects, mean ± SD
0.12 ± 0.981 -0.61 ± 1.097 -0.62 ± 1.367 \0.001
P value versus placebo \ 0.001 \ 0.001
P value versus caffeine 200 mg 0.9328
Computerized quantitation analysis
Number of segments with reversible
defects, mean ± SD
MPI-2 (regadenoson alone) 1.47 ± 1.927a 2.00 ± 2.364b 2.19 ± 2.122c
MPI-3 (regadenoson ? placebo or
caffeine)
1.74 ± 2.355 1.46 ± 1.954 1.42 ± 1.794
Change in number of segments with
reversible defects, mean ± SD
0.31 ± 1.622a -0.59 ± 1.743b -0.81 ± 1.812c 0.0037
P value versus placebo 0.0089 0.0016
P value versus caffeine 200 mg 0.5654
SD standard deviation
* P value is from the primary analysis using analysis of covariance
 The unadjusted P values for pairwise differences should be used for interpretation only if the P value for the treatment effect is B0.05
a n = 64
b n = 69
c n = 70
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review of the scans with significant ischemia, there does
not appear to be any clinically significant TID.
Safety and tolerability
Based upon the safety analysis set, similar proportions of
subjects in the 3 treatment groups reported adverse events
(Table 4), the most common being dyspnea and headache.
Most adverse events were of mild or moderate intensity.
The number of adverse events considered by the investi-
gator as possibly or probably related to regadenoson was
also balanced across the three groups. Adverse events led
to the discontinuation of one subject in the regadeno-
son ? placebo group (elevated cardiac markers) and three
subjects in the regadenoson ? caffeine 200 mg group
(infusion site extravasation, angina pectoris [serious
adverse event, considered unrelated to regadenoson or
caffeine by the investigator], and nausea and vomiting). A
post hoc analysis in patients who received intervention
showed that the chance of having a headache at MPI-3 was
51 % lower for subjects who received caffeine 200 mg and
70 % lower for those who received caffeine 400 mg versus
placebo (Table 5).
No clinically important differences were noted between
the treatment groups in blood cardiac markers, laboratory
parameters, physical examination findings, or electrocar-
diographic abnormalities. Vital sign monitoring at MPI-3
revealed a tendency for systolic blood pressure to be higher
after the administration of caffeine versus placebo; the
difference (approximately 9 mmHg) was significant
(P \ 0.05) at the 15- and 30-min post-regadenoson
assessments for subjects who received 200 mg caffeine,
and at all assessments from 3 min before, to 180 min post-,
regadenoson for subjects who received 400 mg caffeine
(Fig. 6). Diastolic blood pressure was also significantly
(P \ 0.05) increased (by approximately 4–6 mmHg)
compared with placebo at the 3-, 15-, and 30-min post-
regadenoson assessments in subjects who received 200 mg
caffeine, and at the 15- and 30-min post-regadenoson
assessments in subjects who received 400 mg caffeine
(Fig. 6). The heart rate response to regadenoson appeared
to be blunted in subjects who received caffeine, being
significantly (P \ 0.05) lower (by approximately
4–13 bpm) compared with placebo at the 3- and 15-min
post-regadenoson assessments in subjects who received
200 mg caffeine, and at all assessments from 3 to 180 min
Fig. 3 Number of segments with reversible defects detected during
MPI 2 and MPI 3 in patients who received placebo (a) and caffeine (b)
Fig. 4 Median number of segments with reversible defects detected
at MPI-2 and MPI-3 in subjects with C3 segments with reversible
defects at MPI-2 who received placebo (a) or caffeine 200 or 400 mg
(b) at MPI-3
Int J Cardiovasc Imaging (2014) 30:979–989 985
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post-regadenoson in subjects who received 400 mg caf-
feine (Fig. 6).
Discussion
This is the first prospectively designed, multicenter trial
that has been performed to evaluate the interaction between
caffeine and a vasodilator stress agent. The primary finding
of this study was that caffeine ingestion 90 min prior to
regadenoson-stress SPECT MPI reduced the mean number
of reversible perfusion defects detected in subjects with a
high likelihood of CAD. A general trend towards detection
of less ischemia following caffeine was observed, indi-
cating the potential for the diagnostic outcome of regade-
noson-stress SPECT MPI being altered by the intake of
caffeine prior to the procedure.
Regadenoson is a low-affinity, selective A2A receptor
agonist. Because of the large A2A receptor reserve in the
coronary arterial bed, low-affinity agonists need only
occupy a relatively small proportion of receptors to pro-
duce rapid and near-maximal coronary vasodilation [14].
On this basis, it might be expected that caffeine would have
a minimal effect on regadenoson-induced coronary hyper-
emia, as suggested by Gaemperli et al. [9]. These authors
found that regadenoson produced an approximate threefold
increase in myocardial blood flow in healthy volunteers
Fig. 5 Summed difference scores (SDS) at MPI-2 and MPI-3 in
subjects with a SDS score C2 who received placebo (a) or caffeine
200 or 400 mg (b) at MPI-3
Table 3 Agreement of MPI-2 and MPI-3 with respect to ischemia size category, as assessed by blinded readers (full analysis set)
Number of segments with reversible defects MPI-3
(regadenoson ? placebo or
caffeine)
Agreement rate ± SE P value*
0 to \2 2 to \5 C5
MPI-2 (regadenoson alone) Placebo (n = 66) 0.527
0 to \2 47 5 0 0.904 ± 0.041
2 to \5 4 7 1 0.583 ± 0.142
C5 0 0 2 1.000 ± 0.000
Caffeine 200 mg (n = 70) 0.000
0 to \2 48 0 0 1.000 ± 0.000
2 to \5 13 7 0 0.350 ± 0.107
C5 1 1 0 0.000 ± 0.000
Caffeine 400 mg (n = 71) 0.003
0 to \2 49 3 0 0.942 ± 0.032
2 to \5 13 3 0 0.188 ± 0.098
C5 0 3 0 0.000 ± 0.000
SE standard error
* P value is for testing equality of MPI-2 and MPI-3 mean scores (0 to \2 = 0; 2 to \5 = 1; C5 = 2)
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with and without prior ingestion of caffeine 200 mg. This
degree of coronary hyperemia lies well within the level
considered adequate to acquire good quality scintigraphic
images during stress MPI. Our results, which demonstrate
significant attenuation of ischemic defects on SPECT
imaging in caffeine-loaded patients are somewhat discor-
dant with those of the study reported by Gaemperli et al.
[9]. One would expect that caffeine would either attenuate
both regadenoson induced PET coronary flow augmenta-
tion and SPECT reversible perfusion defects, or neither.
However, there are some important differences between the
study reported by Gaemperli et al. and the current study.
Firstly, PET myocardial flow calculations take into account
a time domain and have their own limitations that are
distinct from those of SPECT static relative perfusion
images. Secondly, the patients in our study were not nor-
mal volunteers but, in accordance with the inclusion cri-
teria, had CAD. Our results are also somewhat discordant
with a smaller study by Zoghbi et al. [15]. In that study,
adenosine induced SPECT ischemic defects were not
attenuated by one 8 oz cup of coffee administered 1 h prior
to testing. The average dose of caffeine in our study was
higher than in the Zoghbi et al. trial, and the number of
patients enrolled was substantially larger (207 compared to
30). Both of these factors might account for the difference
in results. It is also possible that caffeine attenuates the
coronary dilating effects of regadenoson more than it does
adenosine, but since caffeine is a non-specific adenosine
antagonist, we believe this explanation is less likely. Since
the current study was designed to match clinical practice,
Table 4 Summary of adverse
events (safety analysis set)
All subjects who received C1
dose of regadenoson, including




a Possibly or probably related
b Medical Dictionary for
Regulatory Activities
(MedDRA) preferred term
c Occurring in[5 % of subjects
d Data include patients with any
exposure to regadenoson. See
post hoc analysis of headache in
subjects with baseline and
randomized exposure
AE, n (%) Regadenoson ? placebo
(n = 113)
Regadenoson ? caffeine
200 mg (n = 116)
Regadenoson ? caffeine
400 mg (n = 116)
AEs 88 (77.9) 92 (79.3) 87 (75.0)
Regadenoson-
related AEsa
87 (77.0) 91 (78.4) 84 (72.4)
Caffeine-related
AEsa
6 (5.3) 7 (6.0) 7 (6.0)
Most common
AEsb,c
Dyspnea 43 (38.1) 47 (40.5) 34 (29.3)
Headached 36 (31.9) 37 (31.9) 38 (32.8)
Flushing 27 (23.9) 29 (25.0) 27 (23.3)
Chest
discomfort
22 (19.5) 25 (21.6) 19 (16.4)
Dizziness 22 (19.5) 25 (21.6) 18 (15.5)
Nausea 13 (11.5) 16 (13.8) 10 (8.6)
Chest pain 8 (7.1) 1 (0.9) 2 (1.7)
Stomach
discomfort
7 (6.2) 4 (3.4) 4 (3.4)
Abdominal
discomfort
6 (5.3) 3 (2.6) 5 (4.3)
Abdominal pain
upper
6 (5.3) 4 (3.4) 5 (4.3)
Dysgeusia 4 (3.5) 11 (9.5) 5 (4.3)
Feeling hot 3 (2.7) 5 (4.3) 6 (5.2)
Table 5 Results of a post hoc analysis in patients who received both scans
MPI-3 (regadenoson ? placebo or caffeine)
Placebo (n = 67) Regadenoson ? caffeine 200 mg
(n = 72)
Regadenoson ? caffeine 400 mg
(n = 72)
No headache Headache No headache Headache No headache Headache
MPI-2 (regadenoson alone) No headache 43 10 47 4 46 3
Headache 4 10 13 8 17 6
Int J Cardiovasc Imaging (2014) 30:979–989 987
123
and since clinicians use the extent and severity of SPECT
reversible defects in decision making, the attenuating effect
of caffeine on these defects should guide testing protocols.
The present clinical recommendation for stress MPI with
regadenoson, according to the prescribing information and
the ASNC imaging guidelines, is to refrain from ingesting
caffeine-containing foods or beverages for 12 h before the
MPI test [1, 8]. Although this restriction is inconvenient for
patients and is often disruptive to the stress laboratory
workflow when patients forget to comply, it appears to be
necessary. The results of the current study indicate that the
inadvertent ingestion of a cup of coffee 90 min prior to the
administration of regadenoson could lead to an underesti-
mation of the ischemic burden detected by regadenoson
stress MPI. Although the effect of caffeine consumption
12 h before testing was not evaluated, the heterogeneity in
caffeine metabolism among individuals and the variability
in caffeine content of a cup of coffee suggests that there is a
potential for an interaction from caffeine administered
several hours prior to regadenoson [16]. The current rec-
ommendation to withhold caffeine-containing products for
C12 h therefore remains appropriate.
The adverse event profile of regadenoson was consistent
with previous studies [12, 13, 17]; no unexpected adverse
events were reported. In a post hoc analysis, prior intake of
caffeine was associated with a decreased incidence of
headache at MPI-3 compared with placebo intake in those
patients who completed the study. Possible explanations
for this finding include blunting of the incidence of caffeine
withdrawal headache in the two caffeine groups, and
counteraction of regadenoson-induced headache by caf-
feine. Cessation of caffeine intake among habitual users is
associated with a withdrawal headache, which typically
develops within 24 h after the previous caffeine ingestion
and is alleviated within 1 h of consuming 100 mg caffeine
[18, 19].
A number of limitations should be considered regarding
the current study results. First, most subjects had only one
segment with a reversible defect at MPI-2, with only 14 %
of subjects having C3 segments with reversible defects.
Although this trial was designed to recruit patients with
significant ischemia on MPI testing, such recruitment
proved to be challenging. This is consistent with the
decreasing frequency and severity of abnormal stress
SPECT MPI studies since 1991 recently reported by Ro-
zanski et al. [20]. A second limitation is that as subjects did
not undergo coronary angiography, the stress scan that
most accurately reflected the result is unknown. Lastly,
because of considerable variability among individual
readings, conclusions based on the mean results should be
interpreted with caution.
In conclusion, this study suggests that the consumption
of caffeine equivalent to 2–4 cups of coffee 90 min prior to
regadenoson-stress SPECT MPI has the potential to
adversely affect clinical interpretation of the acquired
images and may affect the diagnostic conclusions drawn.
These results support pre-procedural directions on caffeine
intake as specified in the regadenoson prescribing infor-
mation and patients should continue to be instructed to
avoid consuming caffeine-containing products for C12 h
prior to the scheduled test.
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